{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T04:11:47Z","timestamp":1744517507721,"version":"3.40.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","geriatriconcology.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jgo.2025.102199","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T21:35:06Z","timestamp":1739655306000},"page":"102199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Updates on myeloma in older adults: Conference summary from the 2024 International Myeloma Society annual meeting"],"prefix":"10.1016","volume":"16","author":[{"given":"Sandra","family":"Frimpong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aminatta Tejan-Kamara","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hira","family":"Mian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya M.","family":"Wildes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"National Cancer Institute","key":"10.1016\/j.jgo.2025.102199_bb0005"},{"key":"10.1016\/j.jgo.2025.102199_bb0010","series-title":"Phase 3 Study Results of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus VRd for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (IMROZ), Clinical Lymphoma, Myeloma and Leukemia","first-page":"S31","volume":"24","author":"Facon","year":"2024"},{"key":"10.1016\/j.jgo.2025.102199_bb0015","series-title":"Isatuximab, Plus Bortezomib, Lenalidomide and Dexamethasone (VRd) for Newly Diagnosed Multiple Myeloma (NDMM) Transplant-ineligible Patients: Frailty Subgroup Analysis of IMROZ, Clinical Lymphoma, Myeloma and Leukemia","first-page":"S290","volume":"24","author":"Manier","year":"2024"},{"key":"10.1016\/j.jgo.2025.102199_bb0020","series-title":"In-Class Transition From Parenteral Bortezomib (V) to Oral Ixazomib in Newly Diagnosed Multiple Myeloma (NDMM): Updated 3-Year PFS Analysis of US MM-6 Overall and by Patient (pt) Subgroups of Interest, Clinical Lymphoma, Myeloma and Leukemia","first-page":"S222","volume":"24","author":"Bernal-Mizrachi","year":"2024"},{"key":"10.1016\/j.jgo.2025.102199_bb0025","series-title":"ASCT: A Viable First-Line Treatment Option for Elderly Multiple Myeloma Patients Without Access to New Drugs, Clinical Lymphoma, Myeloma and Leukemia","first-page":"S225","volume":"24","author":"Am\u00e9rico","year":"2024"},{"issue":"17","key":"10.1016\/j.jgo.2025.102199_bb0030","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral Ixazomib, Lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2025.102199_bb0035","series-title":"Real-world Effectiveness of Ixazomib, Lenalidomide, and Dexamethasone (IRd) in Asian Patients with Relapsed\/Refractory Multiple Myeloma (RRMM), Clinical Lymphoma, Myeloma and Leukemia","first-page":"S263","volume":"24","author":"Moon","year":"2024"},{"key":"10.1016\/j.jgo.2025.102199_bb0040","series-title":"All Oral Triplet Iberdomide Ixazomib and Dexamethasone in Elderly Patients with Multiple Myeloma Patients at First Relapse: Results of the IFM Phase 2 Study I2D, Clinical Lymphoma, Myeloma and Leukemia","first-page":"S38","volume":"24","author":"Touzeau","year":"2024"},{"key":"10.1016\/j.jgo.2025.102199_bb0045","series-title":"Carfilzomib Dosing in Multiple Myeloma: An International Survey of Oncologist Practices, Clinical Lymphoma, Myeloma and Leukemia","first-page":"S252","volume":"24","author":"Dong","year":"2024"},{"key":"10.1016\/j.jgo.2025.102199_bb0050","series-title":"Impact of Age and Frailty on Outcomes of Patients with Multiple Myeloma Receiving CAR T-Cell Theapies \u2013 A Single Center Experience, Clinical Lymphoma, Myeloma and Leukemia","first-page":"S40","volume":"24","author":"Abdallah","year":"2024"},{"issue":"13","key":"10.1016\/j.jgo.2025.102199_bb0055","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2025.102199_bb0060","series-title":"Application of the IMWG Frailty Score in Newly Diagnosed Multiple Myeloma Patients in a Brazilian Cohort, Clinical Lymphoma, Myeloma and Leukemia","first-page":"S129","volume":"24","author":"Santos","year":"2024"},{"key":"10.1016\/j.jgo.2025.102199_bb0065","series-title":"Correlation of the G8 Screening Exam With the Comprehensive Geriatric Assessment in Elderly Undergoing Autologous Hematopoietic Stem Cell Transplantation \u2013 Experience From a Single Center in Brazil, Clinical Lymphoma, Myeloma and Leukemia","first-page":"S127","volume":"24","author":"Silveira","year":"2024"},{"key":"10.1016\/j.jgo.2025.102199_bb0070","series-title":"The Significance and Predictive Performance of Gait Speed and Grip Strength in Dynamic Frailty Assessment of Newly Diagnosed Transplant Non-Eligible Elderly Patients With Multiple Myeloma, Clinical Lymphoma, Myeloma and Leukemia","first-page":"S250","volume":"24","author":"Zue","year":"2024"},{"key":"10.1016\/j.jgo.2025.102199_bb0075","series-title":"Gait Speed, Grip Strength, and Clinical Outcomes in Newly Diagnosed Transplant Non-Eligible os With Multiple Myeloma, Clinical Lymphoma, Myeloma and Leukemia","first-page":"S250","volume":"24","author":"Zue","year":"2024"},{"issue":"3","key":"10.1016\/j.jgo.2025.102199_bb0080","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2352-3026(18)30220-5","article-title":"A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK myeloma research Alliance risk profile): a development and validation study","volume":"6","author":"Cook","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jgo.2025.102199_bb0085","series-title":"Combination of Geriatric Assessment and Clinical Factors to Predict the Survival of Elderly Patients With Myeloma, Clinical Lymphoma, Myeloma and Leukemia","first-page":"S113","volume":"24","author":"Jin","year":"2024"},{"key":"10.1016\/j.jgo.2025.102199_bb0090","series-title":"Gut Microbiota Differences Among Transplant Ineligible Patients With Newly-Diagnosed Multple Myeloma Treated With dara-len-dex, Clinical Lymphoma, Myeloma and Leukemia","first-page":"S131","volume":"24","author":"Abed","year":"2024"},{"key":"10.1016\/j.jgo.2025.102199_bb0095","series-title":"Diagnostic Value of Echocardiography in Multiple Myeloma Complicated with Cardiac Amyloidosis, Clinical Lymphoma, Myeloma and Leukemia","first-page":"S111","volume":"24","author":"Chengcheng","year":"2024"},{"key":"10.1016\/j.jgo.2025.102199_bb0100","series-title":"Assessment of Quality of Life, Frailty, Socioeconomic Status and Clinical Characteristics of Patients with Multiple Myeloma, Clinical Lymphoma, Myeloma and Leukemia","first-page":"S104","volume":"24","author":"Bretas","year":"2024"},{"key":"10.1016\/j.jgo.2025.102199_bb0105","series-title":"Fall Risk Assessment and Fall Prevention in Patients With Multiple Myeloma: First Results of the MYFALL-Trial, Clinical Lymphoma, Myeloma and Leukemia","first-page":"S107","volume":"24","author":"Burghardt","year":"2024"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406825000153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406825000153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T23:43:30Z","timestamp":1744501410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406825000153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1879406825000153"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2025.102199","relation":{},"ISSN":["1879-4068"],"issn-type":[{"type":"print","value":"1879-4068"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates on myeloma in older adults: Conference summary from the 2024 International Myeloma Society annual meeting","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2025.102199","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"102199"}}